

BCAL PRESENTATION ACCEPTED FOR 2022 ASCO ANNUAL MEETING

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce that its proposed presentation titled "Detection of early-stage breast cancer in women by plasma lipidomic profiling" has been accepted for a poster presentation at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting this week.

The annual event, taking place in Chicago, USA on 3-7 June 2022, is attended by more than 40,000 oncology professionals where clinical advances in every area of cancer research are discussed and presented.

Clinical Associate Professor Gillian Lamoury of the University of Sydney, also Radiation Oncologist at Genesis Care, will join BCAL Chief Scientific Officer Dr Amani Batarseh to present BCAL's poster in the Breast Cancer-Local/Regional/Adjuvant session.

The potential of BCAL's blood test to detect early-stage breast cancer in women and the potential for it to be an adjunct to the gold standard technique of mammography will be the focus of BCAL's presentation.

The summary of the presentation (abstract) can be viewed at: <https://meetings.asco.org/abstracts-presentations/211710>

This ASX announcement has been approved for release by the Board of BCAL.

ENDS

Investor & Media Enquiries

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
+61 451 896 420

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>